This course has expired. You can still review the content but course credit is no longer available.
This work is based on a virtual roundtable discussion hosted by Evolve Medical Education LLC.
Although uncommon, scleritis is a dangerous immune-mediated disease that can potentially threaten the structural integrity of the eye and may be indicative of potentially life-threatening systemic vasculitis. Data on the genetic factors of scleritis is lacking, but it is thought that genes affecting systemic autoimmune diseases impact scleritis as well. Differentiating between episcleritis and scleritis and posterior and anterior scleritis can be challenging for physicians. An accurate diagnosis is critical to properly treat the disease and prevent vision loss. In the following summary of a roundtable discussion, experts comment on the complexity in diagnosing scleritis, compare the efficacy of therapeutics based on patient presentation, and review treatment plans for patients who are refractory or nonresponders.
This work was supported by an unrestricted medical writing grant from Mallinckrodt Pharmaceuticals.
MELISSA TOYOS, MD
Partner and Director of Research
THOMAS A. ALBINI, MD
Professor of Clinical Ophthalmology University of Miami Health
Bascom Palmer Eye Institute
STEPHEN D. ANESI, MD, FACS
Massachusetts Eye Research & Surgery Institution
DAVID S. CHU, MD
Medical Director, Metropolitan Eye Research
& Surgery Institute
Associate Professor of Clinical Ophthalmology
ROBERT C. WANG, MD
Texas Retina Associates